Payment overview · 2025
General Payments
$421.30
17 reported records · 10 companies
Healthcare provider profile · identity verified
Russell Anderson
Allopathic & Osteopathic Physicians|Internal Medicine · SMITHFIELD, NC · NPI 1801963376
Verified facts
What the public records show
CMS Open Payments records show Russell Anderson received $421.30 in general payments during 2025 across 17 reported records.
Daiichi Sankyo Inc. accounted for 37.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Calquence by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAGRISSO as an associated drug or biological on 5285 records involving 2776 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tagrisso by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Eliquis by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported POMALYST as an associated drug or biological on 282 records involving 237 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Pomalyst by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Imbruvica by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $159.85 | 37.9% | 4 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $51.12 | 12.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.78 | 8.7% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $34.97 | 8.3% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $33.50 | 8.0% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $32.61 | 7.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.96 | 5.2% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $21.45 | 5.1% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $15.38 | 3.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.68 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $341.31 | 16 |
| Education | $79.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $159.85 | 4 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $51.12 | 2 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Drug | AstraZeneca Pharmaceuticals LP | $36.78 | 2 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $34.97 | 2 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $33.50 | 2 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $32.61 | 1 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $32.61 | 1 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| Somatuline Depot Normalized: somatuline depot |
Drug | Ipsen Biopharmaceuticals, Inc | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| IMDELLTRA (AMG757) Normalized: imdelltra amg757 |
Biological | Amgen Inc. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
| LUMAKRAS Normalized: lumakras |
Drug | Amgen Inc. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TAGRISSO open payments reported associated product |
CMS Open Payments — General Payments 5285 supporting records · 2776 recipient NPIs · example record 1206131546 |
Tagrisso · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
195 | 40 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | POMALYST open payments reported associated product |
CMS Open Payments — General Payments 282 supporting records · 237 recipient NPIs · example record 1184378437 |
Pomalyst · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
195 | 40 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 399 | 75 |
| Oxycodone Hcl | Oxycodone Hcl | 288 | 52 |
| Ondansetron Hcl | Ondansetron Hcl | 198 | 89 |
| Eliquis | Apixaban | 195 | 40 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 195 | 103 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 185 | 61 |
| Prednisone | Prednisone | 184 | 57 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 174 | 37 |
| Trazodone Hcl | Trazodone Hcl | 130 | 42 |
| Sertraline Hcl | Sertraline Hcl | 125 | 26 |
| Gabapentin | Gabapentin | 124 | 35 |
| Olanzapine | Olanzapine | 117 | 44 |
| Valacyclovir | Valacyclovir Hcl | 110 | 24 |
| Fentanyl | Fentanyl | 108 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 27 |
| Alendronate Sodium | Alendronate Sodium | 98 | 25 |
| Furosemide | Furosemide | 98 | 33 |
| Potassium Chloride | Potassium Chloride | 91 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 27 |
| Omeprazole | Omeprazole | 76 | 20 |
| Exemestane | Exemestane | 67 | 15 |
| Dexamethasone | Dexamethasone | 65 | 44 |
| Lorazepam | Lorazepam | 63 | 25 |
| Azithromycin | Azithromycin | 62 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 14 |
| Hydroxyurea | Hydroxyurea | 60 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 59 | 21 |
| Alprazolam | Alprazolam | 56 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 54 | 30 |
| Methylprednisolone | Methylprednisolone | 52 | 40 |
| Revlimid | Lenalidomide | 45 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 16 |
| Xtampza Er | Oxycodone Myristate | 42 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 38 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Fluconazole | Fluconazole | 37 | 20 |
| Meloxicam | Meloxicam | 37 | suppressed |
| Ninlaro | Ixazomib Citrate | 37 | suppressed |
| Mirtazapine | Mirtazapine | 35 | 13 |
| Loperamide | Loperamide Hcl | 34 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 33 | 13 |
| Montelukast Sodium | Montelukast Sodium | 33 | 12 |
| Ondansetron Odt | Ondansetron | 32 | 15 |
| Tamoxifen Citrate | Tamoxifen Citrate | 32 | suppressed |
| Letrozole | Letrozole | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 29 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 22 |
| Imbruvica | Ibrutinib | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Brukinsa | Zanubrutinib | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 14 |
| Celecoxib | Celecoxib | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 16 |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 20 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 11 |
| Hydromorphone Hcl | Hydromorphone Hcl | 19 | suppressed |
| Losartan Potassium | Losartan Potassium | 19 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | 12 |
| Famotidine | Famotidine | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Pomalyst | Pomalidomide | 16 | suppressed |
| Cabometyx | Cabozantinib S-Malate | 15 | suppressed |
| Lenalidomide | Lenalidomide | 15 | suppressed |
| Lisinopril | Lisinopril | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Calquence | Acalabrutinib Maleate | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Dronabinol | Dronabinol | 13 | suppressed |
| Forteo | Teriparatide | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 13 | suppressed |
| Tagrisso | Osimertinib Mesylate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Alecensa | Alectinib Hcl | 12 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 12 | suppressed |
| Promacta | Eltrombopag Olamine | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Veozah | Fezolinetant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $421.30 · 17 records | Daiichi Sankyo Inc. | ERLEADA, Enhertu, IMDELLTRA (AMG757), JEMPERLI, KEYTRUDA, LUMAKRAS, LYNPARZA, OJJAARA, OPDIVO, Onivyde, REBLOZYL, Somatuline Depot, Vonjo, WELIREG, ZEJULA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error